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ABSTRACT:
Introduction: To compare the efficacy and safety of 25g vs. 50g of intravaginal (Posterior fornix) misoprostol for 
induction of labor in 100 patient from Jan 2012 to Dec 2012 at Lumbini Medical College. Methods: One hundred 
pregnant lady requiring induction were randomly assigned to receive either 25 g (group A=50) or 50 g (group B=50) 
of intra vaginal misoprostol every 4 hrs till adequate contractions were achieved or maximum dose of 150 g was used. 
Results: The onset of contraction was earlier in group B in 34 cases as compared to group A, where only 25 cases 
had earlier contraction ( P> 0.05). 38 cases (76%) in Group B and 35 cases (70%) in Group A delivered vaginally. 
Induction to delivery interval was shorter(<12hrs) in group B in 15 cases and in 10 cases in group A. Mean dose of 
Misoprostol (94micrograms) for successful induction in group B was high compared to Group A (75.5 microgram). 
Requirement for oxytocin infusion was higher in group A, 26% vs. 15%. Abnormal contractility pattern was seen in 
B group 24% cases compared to 14% cases in Group A. APGAR score < 7 at 1 min was seen in 26% neonates in 
Group B and in only 10% neonates in Group A. Ruptured uterus did not occur in any group. Conclusion: 50 g dose of 
misoprostol is more efficacious than 25 g dose as seen in our study. However it appears to be less safe both for mother 
and baby due to the high incidence of tachysystole, hyperstimulation and intrauterine passage of meconium.
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 Misoprostol  is a new agent for labour Induction. 
It was found that it had excellent cervical ripening and 
is uterotonic agent. Though not USFDA (United States 
Federation for Drug Adminstration) approved it is being 
increasingly used in medical Abortion, Cervical Repining 
before surgical abortion. However FDA recognizes 
that in certain circumstances off label use of approved 
products are appropriate, rational, and accepted medical 
practice.1Advandtage of misoprostol over other inducing 
agents include stability at room temperature, low cost, 
variety of routes and can be used in different dose. This 
study was planned to compare the efficacy and safety of 
25g vs 50g intravaginally misoprostol for induction labour.
METHODS:
 The study was carried out on pregnant lady (37 
weeks or more of Gestation) requiring induction of labour 
for any medical or obstetrical indication. The study duration 
was of 1 year and it was approved by the ethical committee 
of the hospital (Lumbini  Medical College).Women with 
singleton pregnancy at 37 or more weeks of gestation 
were included after informed consent. Pregnant lady with 
favorable cervix (Bishop score > 6), any contraindication 
to vaginal birth, previous c/s. and PROM (premature 
rupture of membrane) were excluded from the study. The 
study included 100 cases pregnant females, out of which 
50 cases received 25 g (group A) or 50 cases received 50 
g (group B) misoprostol intravaginaly in posterior vaginal 
fornix. The drug was repeated every 4hrs till regular 
adequate uterine contractions were achieved or maximum 
up to 150 g of dose of the drug was used up. Female with 
inadequate contractions or no uterine contractions despite 
of 150 g dose were augmented using oxytocin. Various 
indication for induction were, postdated pregnancy 78%, 
oligohydromnios 12%, hypertension 10%. 
RESULTS:
 The Induction to delivery interval was shorter 
in Group B as shown in Table 1.There was no difference 
between the both group with respect to mode of delivery 
(vaginal) 35 cases (70%) in group A and 38 cases (76%) in 
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group B. The onset of contraction was earlier in group B 
in 34 cases as compared to group A, where only 25 cases 
had earlier contraction (P> 0.05). 38 cases (76%) in Group 
B and 35 cases (70%) in Group A delivered vaginally. 
Induction to delivery interval was shorter (<12hrs) in 
group B in 15 cases and in 10 cases in group A. Mean 
dose of Misoprostol (94 µg) for successful induction 
in group B was high compared to Group A (75.5 µg). 
Misoprostol related side effect, especially gastrointestinal 
side effect (nausea, vomitting, diarrhea, fever, headache) 
were common with group B as compare to group A 
(30%vs 25%), which is not statically significant. Failed 
induction in group A was seen in 7 cases and in 2 cases in 
group B. Requirement for oxytocin infusion was higher 
in group A, 26% vs. 15% . Abnormal contractility pattern 
was seen in B group 24% cases compared to 14% cases 
in Group A, both statically not significant, as shown in 
Table 2. APGAR score < 7 at 1 min was seen in 26% 
neonates in Group B and in only 10% neonates in Group 
A as shown in Table 3. Of all the patient who underwent 
Caesarian Section, various indication for LSCS(lower 
segment Caesarian Section) was irregular FHS(Fetal 
Heart Sound), Meconium Stained liquor, failed induction. 
Common Indication for LSCS was fetal distress,10 cases 
in group B and 8 cases in group A.
revealed that low doses of Misoprostol required more 
oxytocin augmentation as in our study (26%Vs 15%, 
P>0.05).3 However, the cases with failed induction were
more common in low dose misoprostol, these finding
was consistent with one of the study of meydanliet et
al.4 Their study also reported that the proportion of
women delivering vaginally with one dose of vaginal
misoprostol was significantly greater in 50 g group (0/49
vs. 41/47;p>0.001) which was not studied in our cases.
In a comparative study reported by Has et al showed the
rate of Cesarian Section due to fetal distress was higher
with higher dose (28.6 vs. 10.3% p>0.05).5 This was
comparable to our study (group B 20 % vs group A 16%).
We observed that the incidence of normal contraclity
pattern (tachysystole, hyperstumulation) was higher in 50
g (24% vs 14%, p>0.05%) was comparable with study by
Sanchez-Ramos et al.6 Minor side effects were common
with higher dose but uterine Rupture did not occur in both
groups in our study. However, there are so many studies
that have reported serious complication with the use of
misoprostol. A systematic review by Wsagner, 16 medico
legal cases agreed with these findings, with uterine rupture
in 7 cases and hypoxic encephalopathy in 14 cases.7
Thomas et al reported rupture uterus in a primigravida
patient after the use of 100 g of misoprostol (25 g given
4hrly).8 Neonatal outcome was also adversely affected in
females who received higher dose. Babies with low Apgar
score, requiring admission were significantly higher in 50
g group. This was in concurrence with the observations
made by Has et al.5 Contrary to this Sanchez-Ramos et
al in their meta-analysis of five randomize clinical trials
reported comparable neonatal outcomes with the two
doses.6
CONCLUSION:
Misoprostol is a  effective agent for labour 
induction. Complication remain a matter of concern. 
These can be minimized by judicious selection of 
misoprostol dose. 25g misoprostol appears to be safer than 
50 g misoprostol due to high incidence of tachysystole, 
hyperstumulation and meconium in 50 g misoprostol. 
Although this requires stastical correlation in larger 
series.
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Table 1: Induction to delivery interval






1 <12 10 15
2 12-24 15 16
3 >24 10 7
Table 2: Abnormal contractility pattern
SNo Indication Group A, n = 50 Group B, n = 50
1 Tachysystole 4(8%) 6(12%)
2 Hypertonus 2(4%) 3(6%)
3 Hyper Stumulation 1(2%) 3(6%)
Total 7(14%) 12(24%)
Table 3: Fetal outcome analysis
SNo Outcome Group A, n=50 Group B, n=50
1 APGAR <7 in 1 min 5 (10%) 13 (26%)
2 APGAR >7 30 (60%) 25 (50%)
3 Resuscitation 7 (14%) 9 (18%)
4 Meconium 6 (12%) 9 (18%)
5 Admission 7 (14%) 10 (20%)
DISCUSSION:
Misoprostol the PGE1 and analogue appears to 
be safe and effective but only the optimal dose needs to 
be determined. In our study induction delivery interval 
was shorter in group B as compared to group A. Lisa et 
al, their study on 399 pregnant females reported shorter 
induction delivery interval in female who recieved 50 
g of misoprostol (826 min vs. 970 min, p>0.02), Few 
cases in both group required oxytocin augmentation 
as in our study.1,2 A Cochrane review by Hofmeyr also 
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